These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31503324)

  • 1. Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.
    Abramson JS; Irwin KE; Frigault MJ; Dietrich J; McGree B; Jordan JT; Yee AJ; Chen YB; Raje NS; Barnes JA; Davis B
    Cancer; 2019 Nov; 125(21):3692-3698. PubMed ID: 31503324
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
    Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
    Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
    Nair R; Neelapu SS
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.
    Graham CE; Jozwik A; Quartey-Papafio R; Ioannou N; Metelo AM; Scala C; Dickson G; Stewart O; Almena-Carrasco M; Peranzoni E; Ramsay AG; Patten PEM; Pertel T; Farzaneh F; Dupouy S; Pepper A; Benjamin R
    Leukemia; 2021 Dec; 35(12):3581-3584. PubMed ID: 34145373
    [No Abstract]   [Full Text] [Related]  

  • 7. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
    Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
    Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.
    Bukhari A; El Chaer F; Koka R; Singh Z; Hutnick E; Ruehle K; Lee ST; Kocoglu MH; Shanholtz C; Badros A; Hardy N; Yared J; Rapoport AP; Dahiya S
    Am J Hematol; 2019 Oct; 94(10):E273-E275. PubMed ID: 31342556
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells.
    Maher J
    Curr Gene Ther; 2014 Feb; 14(1):35-43. PubMed ID: 24365143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pluripotent stem cell-derived CD19-CAR iT cells effectively eradicate B-cell lymphoma in vivo.
    Lv C; Chen S; Hu F; Huang D; Wang T; Du J; Wang J; Wu H
    Cell Mol Immunol; 2021 Mar; 18(3):773-775. PubMed ID: 32541834
    [No Abstract]   [Full Text] [Related]  

  • 12. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
    Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
    J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.
    Jacobson CA
    J Clin Oncol; 2019 Feb; 37(4):328-335. PubMed ID: 30557517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Salles G; Sesques P; Ferrant E; Safar V; Ghesquieres H; Bachy E
    Bull Cancer; 2018 Dec; 105 Suppl 2():S168-S177. PubMed ID: 30686355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting high-grade B cell lymphoma with CD19-specific T cells.
    Lehmann FM; Maurberger A; Feicht S; Helm F; Ladinig C; Kieback E; Uckert W; Kammertöns T; Kremmer E; Mautner J; Gerbitz A; Bornkamm GW
    Int J Cancer; 2014 Sep; 135(5):1153-64. PubMed ID: 24500882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
    Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
    Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.